[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100526503":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":29,"centralContacts":36,"locations":29,"responsibleParty":44,"collaborators":29,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":48,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":29,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":70,"whyStopped":29,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":76,"leadSponsor":78,"locationsCount":29},{"fullName":5,"class":6},"The Affiliated Hospital of Hangzhou Normal University","OTHER",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Pioglitazone metformin tablets","EXPERIMENTAL","Pioglitazone metformin tablets 15mg\u002F500mg (To control the fasting blood glucose below 7.0mmol\u002Fl, adjust the dose and dosage according to the blood glucose)",[13],"Drug: Pioglitazone metformin tablets",{"label":15,"type":16,"description":17,"interventionNames":18},"Other drug","ACTIVE_COMPARATOR","Chinese patent medicine or Hypoglycemic drugs other than pioglitazone metformin tablets, pioglitazone, metformin and GLP1 ((To control the fasting blood glucose below 7.0mmol\u002Fl)",[19],"Drug: Other drugs",{"label":21,"type":6,"description":21,"interventionNames":22},"Drug-free",[23],"Other: Drug-free",[25,30,34],{"type":26,"name":9,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","Drug intervention for 24 weeks and follow-up for another 72 weeks (fasting blood glucose was controlled below 7.0mmol\u002Fl throughout the study)",[9],null,{"type":26,"name":31,"description":32,"armGroupLabels":33,"otherNames":29},"Other drugs","Chinese patent medicine or hypoglycemic drugs other than pioglitazone metformin tablets, pioglitazone, metformin, GLP1",[15],{"type":6,"name":21,"description":21,"armGroupLabels":35,"otherNames":29},[21],[37,42],{"name":38,"role":39,"phone":40,"phoneExt":29,"email":41},"Junping Shi, Doctor","CONTACT","15869151180","20181580@hznu.edu.cn",{"name":43,"role":39,"phone":40,"phoneExt":29,"email":41},"Jing Liu",{"type":45,"investigatorFullName":29,"investigatorTitle":29,"investigatorAffiliation":29,"oldNameTitle":29,"oldOrganization":29},"SPONSOR","100526503","study-on-mafld-related-cirrhosis-prevention-and-treatment-strategies-100526503",false,"NCT06135584","Study on MAFLD-related Cirrhosis Prevention and Treatment Strategies","Prospective Cohort Study on MAFLD-related Cirrhosis Prevention and Treatment Strategies","SMART","Inclusion Criteria:\n\n1. Age 18-75 years old, gender and ethnicity are not limited;\n2. Meet the diagnostic criteria for MAFLD;\n3. F0-F4 stage of liver fibrosis confirmed by liver biopsy within 24 weeks;\n4. Be willing to sign informed consent.\n\nExclusion Criteria:\n\n1. Cirrhosis due to any chronic liver disease other than MAFLD (including but not limited to alcohol or drug abuse, medications, chronic hepatitis B or C, autoimmune, hemochromatosis, Wilson's disease, alpha1-antitrypsin deficiency);\n2. Any clinical evidence or history of peritonitis, varicose bleeding, or spontaneous encephalopathy;\n3. According to the investigators' assessment, a history of heavy drinking for more than 3 months continuously within the previous year was selected. (Note: Heavy drinking was defined as more than 20 g per day on average for female subjects and more than 30 g per day for male subjects).\n4. Use of NAFLD-related medication history (amiodarone, methotrexate, systemic glucocorticoids, tetracycline, tamoxifen, larger than hormone replacement doses of estrogen, anabolic steroids, valproic acid, and other known hepatotoxins) for more than 2 weeks within the year prior to screening.","ALL","18 Years","75 Years",{"count":58,"type":59},1000,"ESTIMATED","INTERVENTIONAL",[62],"NA","To establish a prospective, multicenter, biopsie-confirmed clinical cohort of MAFLD-related cirrhosis (F3-F4) in China, and analyze the clinical, histopathological features and natural outcomes of MAFLD-associated liver fibrosis\u002Fcirrhosis in China. And than to conducted a real-world study of different strategies of Chinese characteristics for the prevention and treatment of MAFLD-related cirrhosis to evaluate the efficacy and safety of the strategies.",[65,66],"Metabolic Dysfunction-associated Fatty Liver Disease","Cirrhosis",[68,69],"Treatment Strategies","Multicenter Real-World Study","NOT_YET_RECRUITING","2023-11-15",{"date":73,"type":74},"2023-11-18","ACTUAL",{"date":73,"type":59},{"date":77,"type":59},"2026-12-31",{"name":5,"class":6}]